scholarly journals Enhancing therapeutic glycoprotein production in Chinese hamster ovary cells by metabolic engineering endogenous gene control with antisense DNA and gene targeting

Glycobiology ◽  
1999 ◽  
Vol 9 (9) ◽  
pp. 841-850 ◽  
Author(s):  
T. G. Warner
1998 ◽  
Vol 16 (5) ◽  
pp. 468-472 ◽  
Author(s):  
Martin Fussenegger ◽  
Stefan Schlatter ◽  
Daniel Dätwyler ◽  
Xenia Mazur ◽  
James E. Bailey

2019 ◽  
Vol 54 ◽  
pp. 54-68 ◽  
Author(s):  
Bhanu Chandra Mulukutla ◽  
Jeffrey Mitchell ◽  
Pauline Geoffroy ◽  
Cameron Harrington ◽  
Manisha Krishnan ◽  
...  

2012 ◽  
Vol 14 (2) ◽  
pp. 81-90 ◽  
Author(s):  
Jong Youn Baik ◽  
Leyla Gasimli ◽  
Bo Yang ◽  
Payel Datta ◽  
Fuming Zhang ◽  
...  

2020 ◽  
Vol 61 ◽  
pp. 301-314 ◽  
Author(s):  
Qiong Wang ◽  
Tiexin Wang ◽  
Shuang Yang ◽  
Sha Sha ◽  
Wells W. Wu ◽  
...  

Pathology ◽  
1993 ◽  
Vol 25 (3) ◽  
pp. 268-276 ◽  
Author(s):  
Wanda B. Mackinnon ◽  
Marlen Dyne ◽  
Rebecca Hancock ◽  
Carolyn E. Mountford ◽  
Adrienne J. Grant ◽  
...  

Author(s):  
Shazid Md. Sharker ◽  
Md. Atiqur Rahman

Most of clinical approved protein-based drugs or under in clinical trial have a profound impact in the treatment of critical diseases. The mammalian eukaryotic cells culture approaches, particularly the CHO (Chinese Hamster Ovary) cells are mainly used in the biopharmaceutical industry for the mass-production of therapeutic protein. Recent advances in CHO cell bioprocessing to yield recombinant proteins and monoclonal antibodies have enabled the expression of quality protein. The developments of cell lines are possible to upgrade specific productivity. As a result, it holds an interesting area for academic as well as industrial researchers around the world. This review will concentrate on the recent progress of the mammalian CHO cells culture technology and the future scope of further development for the mass-production of protein therapeutics.


Sign in / Sign up

Export Citation Format

Share Document